Skip to search formSkip to main contentSkip to account menu

NO 1886

Known as: NO-1886 
National Institutes of Health

Related topics

Related topics

1 relation
Ibrolipim

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
NO-1886 Up-regulates Niemann–Pick C1 Protein (NPC1) Expression Through Liver X Receptor α Signaling Pathway in THP-1 Macrophage-Derived Foam Cells
BackgroundThe Niemann–Pick C1 (NPC1) protein regulates the transport of cholesterol from late endosomes/lysosomes to other… 
2009
2009
Evaluation of induction potency of new drug candidates on CYP1A2 and CYP3A4 using real-time one-step RT-PCR in primary cultures of cryopreserved human hepatocytes.
SUMMARY This study evaluates the induction potency of new drug candidates on mRNA levels of CYP1A2 and CYP3A4 in primary cultures… 
2006
2006
Assessment of induction of cytochrome P450 by NO-1886 (ibrolipim), a lipoprotein lipase-promoting agent, in primary cultures of human hepatocytes and in female rat liver.
The mRNA levels of human cytochrome P450 (CYP)2Cs and CYP3As in primary cultures of freshly isolated human hepatocytes were… 
2003
2003
Pharmacokinetics and metabolism of NO-1886, a lipoprotein lipase-promoting agent, in cynomolgus monkey
1. The study was conducted to investigate the pharmacokinetics and metabolism of NO-1886 (diethyl 4-[(4-bromo-2-cyanophenyl… 
2002
2002
Phosphonate O-deethylation of [4-(4-bromo-2-cyano-phenylcarbamoyl) benzyl]-phosphonic acid diethyl ester, a lipoprotein lipase-promoting agent, catalyzed by cytochrome P450 2C8 and 3A4 in human liver…
NO-1886 ([4-(4-bromo-2-cyano-phenylcarbamoyl) benzyl]-phosphonic acid diethyl ester) increases lipoprotein lipase activity… 
2001
2001
Lipoprotein lipase activator NO-1886 suppresses atherosclerosis in aorta of diabetic rabbits
AIM To ascertain whether NO 1886 lowers plasma glucose and suppresses atherosclerosis in high fat/high sucrose induced diabetic… 
2000
2000
Effects of NO-1886, a Lipoprotein Lipase Promoting Agent, on Homozygous and Heterozygous Watanabe Heritable Hyperlipidaemic Rabbits
Summary The novel compound NO-1886 ([4-(4-bromo-2-cyano-phenylcarbamoyl)-benzyl]-phosphonic acid diethyl ester, CAS 133208-93-2… 
1997
1997
The novel compound NO-1886 activates lipoprotein lipase in primary cultured adipose and skeletal muscle cells.
As previously reported, we have discovered that a novel compound, NO-1886 (diethyl 4-[(4-bromo-2-cyanophenyl)carbamoyl… 
1996
1996
Suppression of hyperlipidemia-associated cataracts in diabetic rats with the lipoprotein lipase activator NO-1886.
Diabetic cataracts are thought to be caused by hyperglycemia associated with disturbed glucose metabolism. Diabetes mellitus… 
1996
1996
Metabolism of diethyl 4-[(4-bromo-2-cyanophenyl)-carbamoyl]benzylphosphonate in the rat.
1. The metabolism of diethyl 4-[(4-bromo-2-cyanophenyl)carbamoyl]benzylphosphonate (NO-1886), an antilipidaemic agent, was… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)